Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-18
    E.g., 2018-08-18

Articles

Pages

6208 items
3:33 PM, Aug 17, 2018  |  BioCentury | Finance

Vaccine volatility

The last two weeks have not been kind to biopharma companies listed on Chinese exchanges, and Thursday’s announcements regarding the resignations of officials over a vaccine scandal could further dampen sentiment. Earlier this month, the...
2:53 PM, Aug 17, 2018  |  BioCentury | Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
1:30 PM, Aug 17, 2018  |  BioCentury | Finance

Location, location, biotech

Chinese real estate investor Xuechao Wang placed a bet on a domestic cancer start up 16 years ago, which helped pave the way for the country’s first homegrown targeted cancer therapy. Now, market growth in...
8:42 AM, Aug 17, 2018  |  BioCentury | Finance

Tracking China

Despite launching amidst a dour market, investor Brad Loncar expects his new exchange-traded fund, the Loncar China BioPharma ETF (NASDAQ:CHNA), to see significant long-term growth. The ETF, which finished the week down $0.32 to $23.47 since...
10:05 AM, Aug 16, 2018  |  BioCentury | Finance

Navigating the Hot Topics landscape

Investors are making aggressive bets on the ability of early stage companies to deliver on the next generation of therapeutics and technologies. But advances in biology and novel technologies come with challenges ranging from unknown...
4:08 PM, Aug 10, 2018  |  BioCentury | Finance

Takeda gets Ambys-tious

After a two-year search, Takeda Pharmaceutical Co. Ltd.’s equity investment and option deal with newco Ambys Medicines finally gets the ball rolling on the pharma’s goal of building a liver franchise within its core area...
2:41 PM, Aug 10, 2018  |  BioCentury | Finance

Wnt to market

With no traditional life science VCs in its syndicate and little publicly disclosed about its science, Samumed LLC was able to raise a $438 million round at a premoney valuation of $12 billion, bringing its...
12:51 PM, Aug 10, 2018  |  BioCentury | Finance

Sound story

Preclinical data supporting Akouos Inc.’s hearing loss program convinced 5AM Ventures to re-up for a $50 million series A round, and those funds plus additions to the Akouos team have the company poised to take...
9:07 AM, Aug 10, 2018  |  BioCentury | Finance

Missing the obvious

Despite the vast amount of venture money being poured into innovation in healthcare, women’s health still remains an underserved market with significant untapped potential. The importance of this for public health is often overlooked in favor...
5:59 PM, Aug 03, 2018  |  BioCentury | Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...

Pages